- SORT OUT III Data Presented at American College of Cardiology Meeting
in Atlanta and Published in the Lancet
Investigators reported the long-term follow-up of the largest randomized
comparison between the CYPHER(R) Sirolimus-eluting Coronary Stent and
Medtronic's Endeavor(R) Stent highlighting significant and sustained clinical
differences. These important findings were presented at the American College
of Cardiology annual meeting, (ACC 2010) in Atlanta and published on-line in
the prestigious journal The Lancet. The CYPHER(R) Stent was associated with
significantly lower rates of death, myocardial infarction (heart attack), and
repeat revascularization (the need for another procedure) than the
Endeavor(R) Stent out to 18 months. This study adds to the unmatched body of
safety and efficacy data on the CYPHER(R) Stent with this comparison to the
more recently approved Endeavor(R) Stent in a contemporary setting.
The large randomized trial SORT OUT III included more than 2,300 patients
across a wide range of lesion and patient complexity. The investigators
reported that the mortality rate (4.4% for Endeavor(R) vs. 2.7% for
CYPHER(R): p<0.035), incidence of heart attacks (2.1% for Endeavor(R) vs. 0.9
% for CYPHER(R): p<0.029), and composite endpoint of MACE (9.7 % for
Endeavor(R) vs. 4.5 % for CYPHER(R): p<0.0001) was significantly lower in
patients receiving CYPHER(R) compared to those receiving Endeavor(R). The
incidence of "definite" late stent thrombosis was higher for Endeavor(R) than
for CYPHER(R), but this difference was not statistically significant (1.1%
for Endeavor(R) vs. 0.5% for CYPHER(R): p<0.13). Coupled with the safety
advantage observed with CYPHER(R), there was an efficacy advantage as well:
CYPHER(R) had significantly less frequent ischemia-driven target lesion
revascularization through 18 months compared to Endeavor(R) (1.7% for
CYPHER(R) vs. 6.1% Endeavor(R): p<0.0001).